Literature DB >> 17004105

Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics.

Shishan Deng1, Hongying Zhou, Ruohong Xiong, Youguang Lu, Dazhong Yan, Tianyong Xing, Lihua Dong, Enjie Tang, Huijun Yang.   

Abstract

The ubiquitin-proteasome system facilitates the degradation of damaged proteins and regulators of growth and stress response. Alterations in this proteolytic system are associated with a variety of human pathologies. By restriction fragment differential display polymerase chain reaction (RFDD-PCR) and matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF-TOF MS) based on two-dimensional polyacrylamide gel electrophoresis (2-DE), differentially expressed genes and proteins of ubiquitin specific proteases (USPs), proteasome subuinits (PSs) and ubiquitin protein ligase E3A (UBE3A) were analyzed between breast cancer and adjacent normal tissues. Some of them were further verified as over-expression by immunohistochemical stain. Five genes of proteasome subunits (PSs), including PSMB5, PSMD1, PSMD2, PSMD8 and PSMD11, four genes of USPs, including USP9X, USP9Y, USP10 and USP25, and ubiquitin protein ligase E3A (UBE3A) were over-expressed (>3-fold) in breast cancer tissue compared to adjacent normal tissue, and over-expression (>4-fold) of proteins of PSMA1 and SMT3A were observed in breast cancer tissue. PSMD8, PSMD11 and UBE3A were further verified as over-expression by immunohistochemical stain. The action of ubiquitin-proteasome system were obviously enhanced in breast cancer, and selectively intervention in action of ubiquitin-proteasome system may be a useful method of treating human breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004105     DOI: 10.1007/s10549-006-9393-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  65 in total

1.  Reduced ubiquitin-specific protease 9X expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cells.

Authors:  Huiwen Hu; Chengyong Tang; Qinghu Jiang; Wei Luo; Jiming Liu; Xufu Wei; Rui Liu; Zhongjun Wu
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

2.  LPS promotes HBO1 stability via USP25 to modulate inflammatory gene transcription in THP-1 cells.

Authors:  Chen Long; Yandong Lai; Jin Li; Jiangsheng Huang; Chunbin Zou
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2018-08-04       Impact factor: 4.490

3.  Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients.

Authors:  Wei Liu; Yanmiao Huo; Jianyu Yang; Xueliang Fu; Minwei Yang; Lingye Tao; Dejun Liu; Junfeng Zhang; Rong Hua; Yongwei Sun
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

4.  RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities.

Authors:  Xiaobin Cui; Hao Peng; Jing Jin; Tingting Li; Shumao Zhang; Tingting Jin; Su Li; Chunxia Liu; Weihua Liang; Feng Li; Yunzhao Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.

Authors:  Jesse L Cox; Phillip J Wilder; Erin L Wuebben; Michel M Ouellette; Michael A Hollingsworth; Angie Rizzino
Journal:  Cancer Biol Ther       Date:  2014-05-19       Impact factor: 4.742

6.  Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically.

Authors:  Shishan Deng; Jianguo Wang; Lingmi Hou; Jinsui Li; Guo Chen; Baoqian Jing; Xiaoming Zhang; Zhengwei Yang
Journal:  Oncol Lett       Date:  2012-10-09       Impact factor: 2.967

7.  Prospective nested case-control study of feature genes related to leukemic evolution of myelodysplastic syndrome.

Authors:  Yan Ma; Bobin Chen; Xiaoping Xu; Guowei Lin
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

8.  Genomics and proteomics approaches to the study of cancer-stroma interactions.

Authors:  Flávia C Rodrigues-Lisoni; Paulo Peitl; Alessandra Vidotto; Giovana M Polachini; José V Maniglia; Juliana Carmona-Raphe; Bianca R Cunha; Tiago Henrique; Caique F Souza; Rodrigo A P Teixeira; Erica E Fukuyama; Pedro Michaluart; Marcos B de Carvalho; Sonia M Oliani; Eloiza H Tajara; P M Cury; M B de Carvalho; E Dias-Neto; D L A Figueiredo; E E Fukuyama; J F Góis-Filho; A M Leopoldino; R C M Mamede; P Michaluart-Junior; R A Moyses; F G Nóbrega; M P Nóbrega; F D Nunes; E F B Ojopi; L N Serafini; P Severino; A M A Silva; W A Silva; N J F Silveira; S C O M Souza; E H Tajara; V Wünsch-Filho; A Amar; C M Bandeira; M A Braconi; L G Brandão; R M Brandão; A L Canto; M Cerione; R Cicco; M J Chagas; H Chedid; A Costa; B R Cunha; O A Curioni; C S Fortes; S A Franzi; A P Z Frizzera; D Gazito; P E M Guimarães; C M Kaneto; R V M López; R Macarenco; M R Magalhães; C Meneses; A M C Mercante; D G Pinheiro; G M Polachini; A Rapoport; C O Rodini; F C Rodrigues-Lisoni; R V Rodrigues; L Rossi; A R D Santos; M Santos; F Settani; F A M Silva; I T Silva; T B Souza; E Stabenow; J T Takamori; P J Valentim; A Vidotto; F C A Xavier; F Yamagushi; M L Cominato; P M S Correa; G S Mendes; R Paiva; O Ramos; C Silva; M J Silva; M V C Tarlá
Journal:  BMC Med Genomics       Date:  2010-05-04       Impact factor: 3.063

9.  Validation of UBE2C protein as a prognostic marker in node-positive breast cancer.

Authors:  D Loussouarn; L Campion; F Leclair; M Campone; C Charbonnel; G Ricolleau; W Gouraud; R Bataille; P Jézéquel
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

10.  Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.

Authors:  F Végran; R Boidot; B Coudert; P Fumoleau; L Arnould; J Garnier; S Causeret; J Fraise; D Dembélé; S Lizard-Nacol
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.